SER130 is a peptide with anti-inflammatory properties.
SER130 is an IL-4 Receptor agonist, an anti-inflammatory peptide compound with a novel mode of action for the treatment of Diabetic Kidney Disease. SER130 stimulates the endogenous anti-inflammatory processes and SER130 reduce specifically inflammatory processes in pharmacological models.
Treatment with ACE-inhibitor antihypertensives is the golden standard of treatment of diabetic kidney disease but that treatment does not cure the disease. Since the inflammation is a progressive process causing loss of the renal function, SER130 could potentially become a very significant combination (add-on) therapy as standard daily treatment in patients with diabetic kidney disease. It is expected that SER130 treatment delays progression or even prevents development of the disease. SER130 may have blockbuster market potential.